Massive Bio, a leader in AI-powered cancer clinical trial enrollment, has published the second issue of Massive Bio magazine. The publication, which had a successful debut in August, features a variety of content for cancer patients and their families, clinicians, and the business community. Featured content in the second issue includes updates on Massive Bio, the latest oncology therapies, cancer and lifestyle, and technology in cancer treatment, as well as stories about cancer patients and their caregivers and advocates.

Beyond Chemotherapy

One of the highlights of the second issue of Massive Bio is an interview with Arturo Loaiza-Bonilla, MD, the company’s chief medical officer and co-founder, who discusses how new oncology treatment options are allowing many cancer patients to go “beyond chemotherapy,” resulting in improved outcomes. The second issue also features news about clinical trials of cutting-edge treatments for myelofibrosis, lymphoma, and melanoma, as well as novel therapies that target cancer biomarkers. In a focus on technology, the role of artificial intelligence (AI) in medicine is examined, including an explanation of how Massive Bio uses AI to identify the right clinical trial for cancer patients.

Taking Care

The cover story of the second issue of Massive Bio, “Taking Care,” looks at caregivers of people with cancer and other chronic conditions, and why they need to care for themselves, too. Another story explores intriguing evidence that diet changes may help prevent and control cancer. Finally, we get to know Brian McCloskey, a patient who is using data to fight prostate cancer, and helping other men do the same; and learn about Pink Fund, an advocacy group that provides financial assistance to breast cancer patients struggling with mounting bills.

Massive Bio magazine is available in English, Italian, Spanish, Polish, and Turkish, and can be read on the company website and various magazine platforms.

Click to read our magazine